Evaluate the Safety and Exploratory Efficacy of GC1119

Inclusion Criteria: * Subjects with a current diagnosis of Fabry's disease * Plasma α-gal activity of ≤ 1.5mnol/hr/ml and have a mutation in α-galactosidase A gene * Males ≥ 16 years old * Subjects capable of performing this clinical trial in an appropriate manner * Informed consent form voluntarily signed by the subject(or his legally acceptable representative if the subject is under 20 years old) to participation in the study * Agreement to contraception during the study period Exclusion Criteria: * Serum creatinine \> 2.5mg/dl * Subjects have a plan to kidney transplantation * Subjects have undergone kidney transplantation * Subjects are currently on dialysis * Subjects have a clinically significant organic disease(cardiovascular, hepatic, pulmonary, neurologic, or renal disease)that in the opinion of the investigator would preclude participation in the trial * Known life-threatening hypersensitivity(anaphylactic reaction) to α-galactosidase * Treatment with another investigational product within 30days from the administration of study drug dosing or plans to be treated with another investigational product during the study period * Known hypersensitivity to any of the ingredients of study drug(including excipients) * Subjects need the medication of prohibited drug * Alcoholism or drug addiction